Hongoseril (Itraconazole)

Hongoseril (itraconazole) is indicated for the treatment of several systemic and localized fungal infections, typically prescribed when oral therapy is required.

• Dermatophyte infections such as tinea corporis, cruris, and pedis, often presenting with ring‑shaped, scaly skin lesions.
• Onychomycosis affecting fingernails or toenails, leading to thickened, discolored, and brittle nail plates.
• Systemic candidiasis, including bloodstream and deep‑tissue involvement, which may cause fever, organ dysfunction, and sepsis.
• Blastomycosis caused by Blastomyces dermatitidis, presenting with pulmonary symptoms and possible skin lesions.
• Histoplasmosis resulting from Histoplasma capsulatum exposure, which can affect lungs, lymph nodes, and other organs.
• Aspergillosis, particularly invasive forms in immunocompromised patients, may involve the lungs, sinuses, or disseminated disease.

• Itraconazole inhibits the fungal enzyme lanosterol 14α-demethylase, a cytochrome P450 isoform required for conversion of lanosterol to ergosterol. By blocking this step, the drug reduces ergosterol synthesis, compromising the integrity of the fungal cell membrane and inhibiting fungal growth. The inhibition is selective for fungal cells, leading to a fungistatic effect at standard concentrations. At higher concentrations it may exhibit fungicidal activity against some yeast species.

Adverse reactions to Hongoseril (itraconazole) vary in frequency and severity. These events are reported in clinical studies and post‑marketing surveillance.

Common

• Nausea, vomiting, or abdominal discomfort, often mild and transient.
• Diarrhea or constipation, which may be accompanied by stomach cramping.
• Headache and dizziness, sometimes related to blood pressure changes.
• Skin rash or pruritus, ranging from mild redness to localized itching.
• Taste alteration or metallic taste, which may affect appetite.

Serious

• Hepatotoxicity, including elevated liver enzymes, hepatitis, or rare cases of liver failure.
• Severe allergic reactions such as anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Cardiac effects including congestive heart failure, reduced ejection fraction, or serious arrhythmias.
• Visual disturbances such as blurred vision or photophobia, rarely leading to permanent impairment.
• Elevated serum concentrations leading to toxicity, especially when combined with CYP3A4 inhibitors.

When prescribing Hongoseril, clinicians should consider several precautions to ensure safe use and minimize risk.

• Pregnancy Category D – use only if potential benefit justifies the risk to the fetus.
• Contraindicated in patients with severe hepatic impairment or active liver disease.
• Baseline and periodic liver function tests are recommended during therapy.
• Caution in patients with congestive heart failure or reduced left‑ventricular function.
• Elderly patients may have increased plasma concentrations; dose adjustment may be needed.
• Avoid use in individuals with known hypersensitivity to itraconazole or other azole antifungals.

Itraconazole has a high potential for drug‑drug interactions because it is both a substrate and a potent inhibitor of CYP3A4 and P‑glycoprotein.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, or St. John’s wort – may markedly reduce itraconazole levels.
• Concurrent use with other azole antifungals (e.g., fluconazole, voriconazole) – can increase toxicity.
• Statins metabolized by CYP3A4, especially simvastatin or lovastatin – risk of severe myopathy.

Use with caution

• Warfarin – itraconazole can enhance anticoagulant effect; monitor INR closely.
• Oral contraceptives – efficacy may be decreased; consider alternative contraception.
• QT‑prolonging agents (e.g., quinidine, sotalol) – increased risk of arrhythmia; monitor ECG.
• Digoxin – plasma levels may rise; monitor for toxicity.